ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $516,799 | +3.1% | 5,519 | -1.7% | 0.01% | +10.0% |
Q2 2023 | $501,317 | -20.6% | 5,617 | -4.6% | 0.01% | -23.1% |
Q1 2023 | $631,204 | -15.8% | 5,887 | -4.1% | 0.01% | -13.3% |
Q4 2022 | $750,000 | -54.1% | 6,141 | -61.2% | 0.02% | -55.9% |
Q3 2022 | $1,633,000 | +4.9% | 15,816 | -5.6% | 0.03% | +13.3% |
Q2 2022 | $1,557,000 | -20.9% | 16,749 | -0.1% | 0.03% | 0.0% |
Q1 2022 | $1,968,000 | -10.0% | 16,771 | +3.2% | 0.03% | -3.2% |
Q4 2021 | $2,186,000 | -7.4% | 16,251 | +9.7% | 0.03% | -13.9% |
Q3 2021 | $2,360,000 | +19.4% | 14,808 | -1.4% | 0.04% | +24.1% |
Q2 2021 | $1,976,000 | +11.3% | 15,020 | +9.0% | 0.03% | +3.6% |
Q1 2021 | $1,776,000 | +25.1% | 13,780 | +61.9% | 0.03% | +21.7% |
Q4 2020 | $1,420,000 | +100.3% | 8,513 | +85.2% | 0.02% | +76.9% |
Q3 2020 | $709,000 | +18.8% | 4,597 | +13.9% | 0.01% | +8.3% |
Q2 2020 | $597,000 | +295.4% | 4,037 | +200.4% | 0.01% | +200.0% |
Q1 2020 | $151,000 | – | 1,344 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |